News

Roquette and Bonumose Sign a Global Cooperation Agreement Supporting Tagatose Growth

Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, and Bonumose, a pioneer in enzymatic solutions for rare monosaccharide production, are pleased to announce the signing of a Cooperation Agreement that aims to advance the development of tagatose, a natural-origin sweetener with clinically proven health benefits.

This collaboration combines Roquette’s extensive experience in starch and starch-based sweetener production with Bonumose’s cutting-edge enzymatic technology. By leveraging the strengths of both companies, the agreement aims to enhance the scalability of tagatose, reaffirming Roquette’s commitment to innovative sugar management solutions.

“Roquette is proud to partner with Bonumose to advance tagatose growth,” expresses Anne Hirsch, Head of Sugar Management at Roquette. “We recognize the potential of Bonumose’s innovative enzyme technology, which produces high-purity tagatose. Our large-scale starch sweetener production expertise can significantly enhance processing efficiency post enzymatic conversion. This partnership aligns with our long-term vision of sustainable production and meeting the growing global demand for sweetening solutions.”

Ed Rogers, CEO of Bonumose, adds: “Tagatose closely matches the taste, flavor, and cookability of white sugar while offering health benefits such as reduced calories and an ultra-low glycemic index. We are excited to collaborate with Roquette, given their engineering prowess, and multiple market routes. We are happy to welcome Roquette into our expanding ecosystem of strategic partners supporting tagatose adoption.”

Read more here.

Recent News

01/14/2025

CvilleBioHub Enters Into A Virginia Collaboration Network And Will Launch New Biotech Accelerator In Charlottesville

The biotechnology and innovation landscape in Virginia is set for significant growth, thanks to a recent award from the state’s GO Virginia economic development program and a strategic partnership between CvilleBioHub and the University of Virginia (UVA).This award will inject a crucial business component into Virginia’s existing biotech ecosystem, bolstering the success of high-potential, early-stage life

01/13/2025

Biotech Executive & Venture Fund Founder Lisa Bowers Named Managing Director of UVA’s New Enterprise Studio

The University of Virginia Licensing & Ventures Group has named accomplished entrepreneur, board member and executive Lisa Bowers managing director of its new Enterprise Studio, a facility in downtown Charlottesville designed specifically for faculty and graduate students who would like help commercializing their research. The Studio is a partnership between UVA LVG and UVA Innovates,

12/19/2024

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces FDA clearance to initiate a new additional Netherton Syndrome (NS) clinical study for QRX003. QRX003 is a topical lotion that contains a broad-spectrum serine protease inhibitor designed to target the kallikreins in